(MR mammography) Magnetic resonance imaging of the breast is particularly useful in evaluation of newly diagnosed breast cancer, in women whose breast tissue is mammographically very dense and for screening in women with a high lifetime risk of breast cancer because of their family history or genetic disposition.
Breast MRI can be performed on all standard whole body magnets at a field strength of 0.5 T - 1.5 Tesla. Powerful gradient strengths over 15 mT/m will help to improve the balance between spatial resolution, scanning speed, and volume coverage. The use of a dedicated bilateral breast coil is obligatory.
Malignant lesions release angiogenic factors that increase local vessel density and vessel permeability. Breast cancer is detectable due to the strong enhancement in dynamic breast imaging that peaks early (about 1-2 min.) after contrast medium injection. If breast cancer is suspected, a breast biopsy may be necessary to secure the diagnosis.

See also Magnetic Resonance Imaging MRI, Biopsy and MR Guided Interventions.

Requirements in breast MRI procedures:
For Ultrasound Imaging (USI) see Breast Ultrasound at Medical-Ultrasound-Imaging.com.

See also the related poll result: 'MRI will have replaced 50% of x-ray exams by'

Short name: CMC 001, central moiety: Mn2+
CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract. Applications are screening of liver tumors/metastases, imaging of the biliary tract and it could be suitable for liver function studies by following the metabolism and excretion of manganese in the liver cells. Several advantages like better images, higher safety, lower costs and less inconvenience for the patient can be expected.
Animal experiments and clinical studies in humans Phase I and Phase II A, have shown excellent contrast enhancing properties with only minimal adverse effects. CMC 001 is under development by the Medicon Valley based CMC Contrast AB to receive a cost effective, safe and highly diagnostic MR contrast medium for abdominal MR imaging. Clinical studies in Phase III are started.

A large network of interconnecting blood vessels at the base of the brain that when visualized resembles a circle, the arteries effectively act as anastomoses for each other. This means that if any one of the communicating arteries becomes blocked, blood can flow from another part of the circle to ensure that blood flow is not compromised.
The circle of Willis is formed by both the internal carotid arteries, entering the brain from each side and the basilar artery, entering posteriorly. The connection of the vertebral arteries forms the basilar artery. The basilar artery divides into the right and left posterior cerebral arteries. The internal carotid arteries trifurcate into the anterior cerebral artery, middle cerebral artery, and posterior communicating artery. The two anterior cerebral arteries are joined together anteriorly by the anterior communicating artery. The posterior communicating arteries join the posterior cerebral arteries, completing the circle of Willis.
The time of flight angiography MRI technique allows imaging of the circle of Willis without the need of a contrast medium (best results with high field MRI). A cerebrovasular contrast enhanced magnetic resonance angiography (MRA) depicts the circle of Willis in addition to the vessels of the neck (carotid and vertebral arteries) with one bolus injection of a contrast agent.

For Ultrasound Imaging (USI) see Cerebrovascular Ultrasonography at Medical-Ultrasound-Imaging.com.

Contrast enhanced MRI is a commonly used procedure in magnetic resonance imaging. The need to more accurately characterize different types of lesions and to detect all malignant lesions is the main reason for the use of intravenous contrast agents.
Some methods are available to improve the contrast of different tissues. The focus of dynamic contrast enhanced MRI (DCE-MRI) is on contrast kinetics with demands for spatial resolution dependent on the application. DCE-MR imaging is used for diagnosis of cancer (see also liver imaging, abdominal imaging, breast MRI, dynamic scanning) as well as for diagnosis of cardiac infarction (see perfusion imaging, cardiac MRI). Quantitative DCE-MRI requires special data acquisition techniques and analysis software.
Contrast enhanced magnetic resonance angiography (CE-MRA) allows the visualization of vessels and the temporal resolution provides a separation of arteries and veins. These methods share the need for acquisition methods with high temporal and spatial resolution.
Double contrast administration (combined contrast enhanced (CCE) MRI) uses two contrast agents with complementary mechanisms e.g., superparamagnetic iron oxide to darken the background liver and gadolinium to brighten the vessels. A variety of different categories of contrast agents are currently available for clinical use.
Reasons for the use of contrast agents in MRI scans are:
Common Indications:
Brain MRI : Preoperative/pretreatment evaluation and postoperative evaluation of brain tumor therapy, CNS infections, noninfectious inflammatory disease and meningeal disease.
Spine MRI : Infection/inflammatory disease, primary tumors, drop metastases, initial evaluation of syrinx, postoperative evaluation of the lumbar spine: disk vs. scar.
Breast MRI : Detection of breast cancer in case of dense breasts, implants, malignant lymph nodes, or scarring after treatment for breast cancer, diagnosis of a suspicious breast lesion in order to avoid biopsy.

For Ultrasound Imaging (USI) see Contrast Enhanced Ultrasound at Medical-Ultrasound-Imaging.com. See also Blood Pool Agents, Myocardial Late Enhancement, Cardiovascular Imaging, Contrast Enhanced MR Venography, Contrast Resolution, Dynamic Scanning, Lung Imaging, Hepatobiliary Contrast Agents, Contrast Medium and MRI Guided Biopsy.

The diethylenetriaminepentaacetic acid-chelate contains five acetate moieties linked by a molecular backbone, which bind a metallic ion complex. This chemical bonding solves the problem of toxicity of, e.g. Gadolinium, because DTPA complexes are very stable.
DTPA is used together with technetium-99m as a nuclear imaging radiopharmaceutical and with gadolinium as a MR contrast medium. DTPA chelates undergo renal glomerular filtration and can be used to quantify it. DTPA is also used as a decontamination agent in individuals who have ingested radioactive materials.